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remaining six program designs can all be considered cost effective depending on 
what the health-care decision makers are ready to pay for gaining a quality-adjusted 
life-year. ConClusions: Based on the results of the simulated screening programs, 
initiation of screening at the age of 75 with repeated screening at 80 years was found 
to be the most cost-effective design of a screening program for unknown AF when 
a QALY is considered to be worth approximately € 50,000.
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objeCtives: Accuracy standards of blood glucose monitoring systems have been 
recently revised. The revised standard, ISO 15197:2013, tightens the range of results 
considered accurate from a 20% deviation from the reference value to a 15%. The 
objective of this analysis is to evaluate the economic value of accuracy differences 
between ISO compliant and non ISO compliant meters in Spain, using a model-
ling approach. Methods: Clinical and economic outcomes were simulated over a 
20-years time horizon by means of a Markov model. 4 health states were considered, 
including no event, non-fatal hypoglycemia, fatal hypoglycemia and death due to 
other causes. Model inputs were derived from published sources. Inputs included 
Spanish Type 2 diabetes mellitus (T2DM) insulin-treated population size, risk of 
severe hypoglycemic event (SHE) due to meter error, cost per SHE and rates of death 
due to SHE and other causes. Results: A reduction of the inaccuracy range from 
20% to 15% would translate into a 25.5% reduction of SHE. The incremental cost per 
SHE avoided would be -2,795€ . The reduction in SHE would lead to cost savings of 
135€ per T2DM insulin-treated patient and year. Considering there are 379,728 T2DM 
insulin-treated patients in Spain, the total cost savings would exceed 51€ million, 
meaning 0.9% of total Spanish diabetes expenditure and 0.07% of total Spanish 
health care expenditure. ConClusions: Self-monitoring blood glucose is a key 
component of diabetes management as it is often used in clinical decision making. 
It is therefore critical that these devices are accurate and precise. The results of 
this study might encourage the conversion of all patients using non ISO compli-
ant meters to ISO compliant meters in the European Union, where ISO 15197:2013 
will become mandatory in May 2016. It might also enhance stricter standards in 
countries where these requirements will not be mandatory.
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invAsive BlADDer cAncer: cOst-cOnsequences During OutPAtient 
surveillAnce in sWeDen
Dansk V1, Malmström P2, Bläckberg M3, Malmenäs M1
1PAREXEL, Stockholm, Sweden, 2Uppsala University, Uppsala, Sweden, 3Helsingborg Hospital, 
Helsingborg, Sweden
objeCtives: Bladder cancer (BC) can be life-long and requires intensive and routine 
monitoring and treatment, which makes it costly and impacts on patients’ health 
perception. Hexaminolevulinate is a photosensitizing agent selectively absorbed by 
cancer cells which light up in red when illuminated with blue light, approved for 
improved detection and management of BC. The objective was to evaluate the cost-
consequences of using Hexaminolevulinate-guided blue-light flexible-cystoscopy 
(HBLFC) as an adjunctive to white-light flexible-cystoscopy (WLFC), compared with 
WLFC alone, in the detection of non-muscle invasive BC (NMIBC) one year after 
diagnosis and recurrence. Methods: A cost-consequence model using a combi-
nation of a decision tree and Markov cohort state transition model structure was 
developed using a Swedish setting, Swedish guidelines and a hospital perspective. 
231 patients were followed in an outpatient setting after diagnosed with NMIBC 
and successfully treated with an initial transurethral resection of bladder tumour 
(TURBT).The 231 patients were distributed across all risk groups. The model cap-
tured costs (2014 SEK) of surveillance and treatment of recurrence and progression 
over a 5-year period using 3-month-cycles. Results: The total cost over five years 
was marginally higher, 1.6%, for HBLFC (SEK 14,033,864) compared to WLFC (SEK 
13,815,155) although cost-saving from year 2. HBLFC resulted in reduced resource 
demand versus the comparator (TURBTs: 121.4 vs 126.1; cystectomies: 56.3 vs 58.8; 
operating room [OR] time [hours]: 428.9 vs 447.4; bed days: 18.7 vs 19.5). High-risk 
patients represented the largest share of the costs but also the main benefits in 
clinical outcomes. ConClusions: HBLFC was cost neutral over 5 years and reduced 
the number of bed days and OR time compared to WLFC alone, resulting mainly 
from fewer TURBTs and cystectomies. The greatest overall benefits were seen among 
high-risk patients, but other risk-groups are likely to benefit as well. Future model 
development will include quality-of-life data.
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objeCtives: The use of antibiotic-laden bone cements in surgical operations of 
the hip aims to help prevent surgical site infections (SSIs) and avoid their negative 
consequences. The objective of this study was to evaluate the costs and conse-
quences for the NHS in England and Wales associated with the use of a dual antibi-
otic cement (COPAL® G+C) compared to a single antibiotic cement (PALACOS® R+G) 
in the treatment of fractured neck of femur with hemiarthroplasty. Methods: A de 
novo decision tree model was developed, incorporating relevant clinical events of 
30-day mortality, superficial and deep SSIs, and revision procedures, over a 1 year 
time horizon. Probabilities were informed by published literature and results of a key 
randomised controlled trial comparing the two interventions. Costs were sourced 
by applying the meta-analytic results to U.S. lengths of stay, costs, and practice pat-
terns. We estimated the annual ARI visit rate for the one million member cohort, 
by setting (inpatient, ICU, outpatient) and ARI diagnosis. Results: In the inpatient 
setting, the costs of procalcitonin -guided care for the one million member cohort 
was $2,083,545, compared to $2,780,322, resulting in net savings of nearly $700,000 
to the IDN for the year 2014. The ICU and outpatient setting, the savings to the IDN 
were $73,326 and $5,329,824, respectively, summing up to overall net savings of 
$6,099,927 for the cohort. Results were robust for all ARI diagnoses. For the whole 
U.S. insured population, procalcitonin-guided care would result in $1.6 billion in 
savings annually. ConClusions: Our results show substantial savings associated 
with procalcitonin protocols of ARI across common U.S. treatment settings. These 
results are robust to changes in key parameters, and the savings can be achieved 
without any negative impact on treatment outcomes.
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objeCtives: The purpose of our analysis was to determine the costs of the con-
ventional three-dimensional radiation therapy (3DCRT) and the normal and hypo-
fractionated intensity-modulated radiation therapy (IMRT and HF-IMRT) for the 
treatment of localized prostate cancer, and to compare the treatment costs with 
the reimbursement fees. Methods: The cost-analysis was performed with micro-
costing method based on the data of a Hungarian oncology center from the per-
spective of the health care provider. We estimated the resource use in each phase 
of the radiation therapy process through face-to-face interviews with radiation 
oncologists, radiation therapists and physicists. The average positioning and treat-
ment delivery time were assessed from the data of 100 fractions delivered in 20 
patients. A unit cost for each cost component was calculated based on the actual 
costs retrieved from the accounting system of the oncology center. We assumed the 
irradiation scheme to use a total of 38 fractions in the 3DCRT and IMRT, and 25 frac-
tions in the hypofractionated scheme. Capital costs were taken into consideration in 
the cost calculation. Costs were converted to EUR by applying actual exchange rates 
(1 EUR = 309 HUF). Results: Based on our calculations the expected mean cost of 
patients undergoing 3DCRT, IMRT and HF-IMRT were 2,105 EUR, 3,066 EUR and 2,244 
EUR respectively. The current reimbursement fee for 38 and 25 fractions are 3,513 
EUR and 2,635 EUR respectively. ConClusions: Although IMRT and HF-IMRT has 
already been proven to be cost-effective compared to 3DCRT, the current reimburse-
ment fees do not encourage healthcare providers to use the more effective therapy 
techniques. The revision of intervention codes, DRGs and cost-weights in terms of 
radiation therapies for prostate cancer is desirable in order to resolve this anomaly.
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objeCtives: According to a number of publications frequency of complaints on 
temporomandibular joints (TMJ) ranges from 27 to 76% and is on a third place in 
modern dentistry after other dental diseases such as caries and its complications 
and periodontal pathology. The necessity of high-quality, relevant and available 
for patient diagnosis is increasing. To evaluate and compare the costs for diagnosis 
of patients with possible TMD from the payer’s perspective in the reform period of 
health care system and implementation of health insurance in Ukraine. Methods: 
For the diagnosis of TMJ violations such alternative methods may be used: ortho-
pantomography (OPG), zonography (ZG), ultrasonography (USG), 3D computed 
tomography (3D CT) and magnetic resonance imaging (MRI). From December 2013 
to June 2015 122 patients with suspected TMD at Prosthetic Dentistry Department 
Danylo Halytsky Lviv National Medical University were examined. Results: The 
above mentioned methods singly and in combination were used for diagnosis. The 
costs of examination according to the average data in private and public clinics in 
Lviv are: OPG - 5-7 € ; ZG - 5-7€ , USG - 7-9 € , 3D CT - 18-30 € , MRI - 30-50 € . Resulting 
62 OPG, 22 ZG, 54 USG, 20 3D CT and 2 MRI were conducted. Consequently, OPG, ZG 
and USG are available for most patients, less available is 3D CT. MRI is the most 
limited method. ConClusions: Such diagnostic methods as OPG, ZG and USG are 
the most available for patients. They are informative, have no excessive radiation 
exposure and allow them to re-apply if the forward observation is necessary. In 
some cases the 3D CT method should be combined with USG, so that complex has 
a higher cost. MRI is the “gold” standard for diagnosis, but the high cost and features 
of study may limit its usage.
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objeCtives: The primary objective of this study was to use computer simulations 
to determine the optimal age for initiation of screening for atrial fibrillation and 
to evaluate if repeated screening is of additional value. Methods: This analysis 
was based on a decision-analytic simulation model. More than one billion different 
designs of screening programs for unknown atrial fibrillation were simulated and 
analyzed. Widely accepted decision rules for mutually exclusive programs were used 
to identify optimal designs for screening for unknown atrial fibrillation. Results: 
Costs and effects generated by the 1,073,741,824 possible screening designs was 
calculated and compared. Of all possible programs, 1,073,741,818 designs were ruled 
out from the analysis based on dominance, extended dominance or the fact that 
the program design had an incremental cost of over € 100 000 per gained QALY. The 
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sedation for endoscopic procedures that compared outcomes using pulse oxime-
try alone with pulse oximetry plus capnography. Adverse events (AEs) considered 
included apnea, bradycardia, desaturation, and hypotension. Interventions to treat 
AEs were taken from guidelines with costs derived from the Premier database and lit-
erature review. Adverse outcomes included unplanned admission and mortality. Odds 
ratio for events with capnography were taken from RCTs and a meta-analysis, where 
available, data specific to moderate sedation were used. The model base case assumed 
no progression into deep sedation and patients with mean characteristics of age 55 
years, body mass index 26 kg/m2, and 45% male. Probabilistic sensitivity analyses 
were performed. Results: In the base case, utilization of capnography reduced the 
proportion of patients experiencing ≥ 1 AE by 18.0% and resulted in 1 AE of any severity 
being avoided every 9 procedures. The mean number needed to treat (95% credible 
interval [CrI]) to avoid an apnea or severe desaturation AE was 27 (−109–409) and 17 
(4–308), respectively. Due to the reduction in AEs, capnography resulted in a saving 
of $55 (95% CrI −96–247) per procedure at 1 year. The key cost driver was reduced use 
of airway interventions with capnography. Assuming that AEs did not incur costs; 
capnography increased the cost per procedure by $9, costing $83 per adverse event 
avoided. ConClusions: Capnography is likely to be cost-effective for monitoring 
moderate sedation even without considering progression to deep sedation. Estimates 
indicate that it may also be cost saving.
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objeCtives: To conduct a cost-effectiveness analysis (CEA) of capsule endos-
copy (CE) used in the indication of diagnosing small bowel Crohn’s disease 
(CD). Methods: A cost-effectiveness analysis was conducted for a one-year time 
horizon, from third-party–payer perspective only including the direct healthcare 
costs, like outpatient care, inpatient care and pharmaceutical consumption. A deci-
sion tree structure was defined with two alternatives: (1) capsule endoscopy (with 
using patency capsule), (2) standard diagnostic package including Calprotectin test, 
ultrasound, colonoscopy with ileoscopy, CT enterography. The costs are expressed 
in monetary value, the effectiveness is measured as the number of patients with 
accurate and appropriate diagnosis (true negative and true positive). The sensitivity 
and specificity for diagnosing CD used as input data of model are based on a review 
of literature. The value of prevalence of CD and the costing estimates are based on 
Hungarian data. Results: To the available sensitivity, specificity for diagnosing 
CD and the prevalence data, the diagnostic accuracy of CE and standard diagnostic 
package used in Hungary are the followings, respectively: true positive (0.7 vs. 0.532), 
true negative (0.273 vs. 0.2518), false negative (0 vs. 0.168), false positive (0.027 vs. 
0.0482). 97 of 100 patients likely to be diagnosed accurately and appropriately using 
CE compared with 78 of 100 patients using standard diagnostic package. As a result 
of CEA, the ICER value is 703,500 HUF per accurately and appropriately diagnosed 
patient. ConClusions: The CE has been used for years in Hungary in given indica-
tions but not in diagnosing small bowel CD. The ICER calculated is lower than the 
threshold of cost-effectiveness set in Hungary. Taken into account the diagnostic 
yield and the advantages of CE, the result of CEA, extending the indications of CE 
for diagnosing small bowel CD should be considered by the Hungarian health policy.
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objeCtives: To evaluate the cost-effectiveness of an imaging diagnostic strategy for 
stable coronary artery disease (CAD) guided by a new model to estimate the pre-test 
likelihood of disease that integrates specific circulating biomarkers with common 
clinical variables using data collected through the EVINCI study. Methods: In the 
clinical standard path (CSP) pre-test likelihood of disease was estimated by the 
Genders model (based on age, sex and symptoms) while the new clinical-biohumoral 
path (CBP) included the integration of previously selected bio-humoral predictors 
of CAD (HDL-cholesterol, aspartate-transaminase and C-reactive protein) to define 
the pre-test likelihood. In both paths, according to the 2013 ESC-Guidelines for 
management of stable CAD, the pre-test likelihood guided further examinations: 
no other test for low probability (< 15%), non-invasive imaging in intermediate prob-
ability (15%-85%) and direct invasive coronary angiography (ICA) for high probability 
(> 85%). Effectiveness was defined in terms of correct diagnosis at ICA. Costs of the 
diagnostic pathways were calculated per-patients considering reimbursement of 
non-invasive and invasive examinations as well as biomarkers assay in the CBP. All 
costs were expressed in Euro 2013. Results: Considering 487 subjects enrolled in 
the EVINCI study because of suspected CAD and having a complete clinical, bio-
humoral and imaging profile, the CBP dominates the CSP being more effective and 
less costly. Specifically, CBP allowed for 90.6% (±29.3%) correct diagnoses with a 
mean cost of 352.9 Euros (±752.5), while CSP correctly diagnosed 88.9% (±29.3%) of 
cases at a mean cost of 615.6 Euros (±861.1). Results did not change when accounting 
for missed CAD diagnoses. ConClusions: The estimation of pre-test likelihood 
of CAD integrating circulating biomarkers and clinical variables allows for more 
accurate and more cost-effective diagnostic strategies, avoiding unnecessary diag-
nostic tests. The new predictive model is an effective gate-keeper to non-invasive 
and invasive imaging tests in patients with symptoms of stable CAD.
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from the perspective of the NHS in England and Wales. Results were expressed 
in terms of accrued costs and consequences, and one-way sensitivity analysis 
(OWSA) and scenario analysis was used to explore key model assumptions and 
inputs. Results: COPAL® G+C was associated with a reduction in the probability 
of a patient suffering either a deep or superficial infection as well as a reduction 
in the probability of experiencing a revision procedure. Overall, cost savings of 
£1,047.73 per patient were achieved with the use of the dual-antibiotic cement. 
OWSA found results to be robust to changes in key model parameters; assump-
tions around probabilities of 30-day survival were a key model driver. Of explored 
scenarios, the greatest impact was observed with the removal of deep SSIs from the 
model, which reduced cost savings to £93.80 per patient. ConClusions: Use of 
dual antibiotic bone cement can lead to reductions in the rate of SSIs and require-
ments for revision surgery. In addition to a clinical benefit, this has the potential to 
generate meaningful cost savings for the NHS in England and Wales.
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objeCtives: A number of studies have reported that up to 27% of adenomas are 
missed during screening colonoscopy for the prevention or detection of colorectal 
cancer (CRC). A suboptimal adenoma detection rate (ADR) is significantly associated 
with a higher incidence of CRC, with adenomas often being located at the proxi-
mal side of a mucosal fold. ENDOCUFF VISION™ is a novel device that sits firmly 
over the tip of the colonoscope, and which, by flattening mucosal folds, has been 
shown to significantly improve ADR. The benefit of using this device in reducing 
interval CRC has been investigated in a cost-consequence model with a 10 year 
time horizon. Methods: The model compares the use of 2L polyethylene glycol 
+ ascorbate components (2LPEG+ASC) as a bowel cleansing preparation, with or 
without use of this device. The additional cost of the device (set at € 30) is modelled, 
together with the potential cost savings through improved ADR and CRC preven-
tion. Model inputs include rates of successful bowel cleansing, number of com-
pleted colonoscopies, ADR, rates of surveillance colonoscopy, associated costs, and 
resource utilisation in a cohort of 10,000 patients who are eligible for screening in 
the German healthcare system. Model outputs include cases of CRC missed or pre-
vented, cost of colonoscopy, and the per person costs. Results: The model shows 
that the improved ADR through the use of this colonoscope device with 2LPEG+ASC, 
compared with 2LPEG+ASC alone, avoids progression to CRC in more individuals. 
Despite an increase in the overall cost due to repeat colonoscopies, the use of the 
device leads to an overall saving in CRC treatment costs of € 5,137,894, resulting in 
a cost saving of € 283 per person screened over 10 years. ConClusions: The use 
of ENDOCUFF VISION™ can improve ADR, which may reduce the development of 
CRC, avoid treatment costs, and reduce mortality.
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objeCtives: To conduct a cost-effectiveness analysis (CEA) of continuous remote 
monitoring (RM) of heart failure (HF) patients with cardiac electronic implantable 
device. Methods: A cost-effectiveness analysis was conducted for a 10-year time 
horizon, from third-party–payer perspective only including the direct healthcare 
costs. A Markov model was adapted with four health states for two alternatives: 
(1) continuous RM with data transmission on a daily basis, (2) conventional, regu-
lar in-office follow-up (CFU). The costing estimates are based on Hungarian data. 
The effectiveness is measured as the number of life years saved. The input data 
of effectiveness are based on randomised clinical trials and data provision of the 
Hungarian National Health Insurance Fund Administration. Results: As a result 
of CEA, 652 life years can be saved in a 10-year time horizon in a patient cohort 
(N= 100). The ICER value is 1.78 million HUF (≈ 5,730 EUR) per life year saved. To our 
estimation 4,500-5,600 HF patients could be continuously remote monitored by 
the end of the 5th year with a gradual inclusion of patients. Taking into account 
the mortality of both arms, under 5 years, extra 520-650 lives (among the gradually 
involved 4,500-5,600 patients) can be saved with using RM compared to the CFU. 
Both to the deterministic and probabilistic sensitivity analysis the ICER calculated 
is relatively robust. ConClusions: The ICER calculated is lower than the thresh-
old of cost-effectiveness set in Hungary. The number of lives can be potentially 
saved is favourable, especially by the HF patient population regarding its relatively 
low 5-year survival rate (below 50%). The Hungarian health policy should consider 
the inclusion of RM into the public reimbursement system and at the same time 
establishing a patient registry for the remotely monitored HF patients to evaluate 
the long term benefits of RM.
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objeCtives: Capnography monitoring is recommended during moderate sedation, 
although its uptake has been restricted by concerns over excess costs and demonstra-
tion of safety benefit. This analysis investigates the cost-effectiveness of capnography 
for moderate sedation during gastrointestinal endoscopy. Methods: Randomized 
clinical trial (RCT) and large-scale study data were used to build a model of moderate 
